PROPEL PHARMA
GenericsPROPEL PHARMA is a generic drug manufacturer focused on Neurology.
PROPEL PHARMA's Key Drugs
PROPEL PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PROPEL PHARMA's Recent FDA Approvals
New NDA/BLA approvals for PROPEL PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
PROPEL PHARMA's Therapeutic Areas
PROPEL PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PROPEL PHARMA's Top Competitors
PROPEL PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PROPEL PHARMA Pipeline Snapshot
Active clinical trials for PROPEL PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2021-07-29
- Latest
- 2024-09-12
- Applications
- 1